Merck × Mayo Clinic
Merck and Mayo Clinic announced a research and development agreement to apply AI and advanced analytics to drug discovery. [40] The collaboration gives Merck access to Mayo Clinic's extensive de-identified multimodal data—including laboratory results, medical imaging, clinical notes, and molecular data—to validate AI models and guide development strategies. [40, 43] The partnership, which is Mayo Clinic's first of this scale with a global biopharma company, will initially focus on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis. [50, 51] Financial terms of the collaboration were not disclosed. [51]
The asset
Access to Mayo Clinic's Platform_Orchestrate program, which includes de-identified clinical and multimodal data sets, registries, biorepositories, and advanced AI tools.
The record
- Seller status
- Going concern
- Sector
- Hospital system / Healthcare provider
- Modalities
- clinical data, genomic, medical imaging, text
- Jurisdiction
- US
- Personal data
- Data is de-identified within a secure platform environment. [40, 43]
What it means if you hold data
This collaboration highlights a major trend of biopharmaceutical companies partnering directly with large hospital systems to access high-quality, multimodal clinical and genomic data at scale. It shows a move to ground AI-driven drug discovery in robust, real-world clinical data to improve target identification and probability of success. [37, 43]